Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Interleukin-2 for Metastatic Kidney Cancer
NCT02964078Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Apr 2017
- Primary completion
- Mar 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in kidney cancer, sponsored by Moffitt Cancer Center. Started Apr 2017; status: completed.
02
Drugs
03
Conditions
kidney cancer
Beyond the preview
Go deeper on NCT02964078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02964078.